Going to LSX World Congress? Join our upcoming panel session featuring Shruti Choudhary MD MBA MS, SVP of Product, right here in Boston on September 11, 2024! 🧠 Learn more about the commercialization process, regulatory complexities, and ethnical implications in the #medtech #SaaMD market. Thank you LSX - partnering for Life Science eXecutives
Elucid
Herstellung medizinischer Geräte
Boston, Massachusetts 5,419 followers
Bringing Imaging to Life
Über uns
Elucid is a Boston-based medical technology company using histology-validated software to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid's CTA analysis equips physicians with critical information designed to enable precision medicine. Elucid is the first non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall. Elucid's unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs.
- Website
-
https://elucid.com
External link for Elucid
- Industrie
- Herstellung medizinischer Geräte
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- Boston, Massachusetts
- Typ
- In Privatbesitz
- Gegründet
- 2013
- Spezialitäten
- cardiovascular, plaque characterization, FFRct, CCTA, Heart Disease, CT Angiography, CCT, Stroke, and Heart Attck
Standorte
-
Primäre
Wegbeschreibung erhalten
399 Boylston St
Suite 400
Boston, Massachusetts 02116, US
Employees at Elucid
Aktualisierungen
-
Missed our session at #SCCT2024? Catch up by watching the recorded symposium here: https://lnkd.in/gjFw-zUd Highlights: review of the current status of plaque quantitation in practice, late-breaking data confirming Elucid's accuracy against ground truth histology, getting involved in Elucid's latest registry (PRE-VUE). Featuring our fantastic speakers Drs Mark Rabbat MD,FSCCT,FACC,FAHA and Matthew Budoff. Thank you to our audience who had excellent questions, and to Society of Cardiovascular Computed Tomography for a great meeting this year! #yesCCT #histology #plaquequantitation #plaquematters #seewhatyoucantreat
Elucid at SCCT 2024: Precision Cardiovascular Pathways with Histology-based Plaque Quantitation
https://www.youtube.com/
-
We support the initiative to double CCTA reimbursements, which will reduce financial strain on medical practices, and in turn enable improved patient equity and access to high quality care. As always, we rally behind causes that promote and sustain advancements in our healthcare system! #yesCCT
We have the opportunity to double payment rates for CCTA through the HOPPS CY25 proposed ruling. Your voice is crucial in this process - send a letter to CMS by Sept 9 to advocate for increased reimbursement. Let's ensure better patient access to cost-efficient CCT testing! https://lnkd.in/e3vb3rwT
-
-
We're #hiring a new Software Engineering Manager - Medical Visualization in Boston, Massachusetts. Apply today or share this post with your network.
-
We're #hiring a new Sales Enablement Lead in Boston, Massachusetts. Apply today or share this post with your network.
-
We're #hiring a new Process Engineer, Clinical Operations in Boston, Massachusetts. Apply today or share this post with your network.
-
We are thrilled to announce Kelly Huang, PhD as Chief Executive Officer at Elucid! As our company continues to prepare for growth, we look forward to welcoming Kelly's valuable experience in successful commercialization launch and expansion as he joins the leadership team. 📍 Read more here: https://lnkd.in/d9hJXTFT
-
-
🚨🫀Final Reminder: Join us at SCCT Friday morning 7AM at Capitol/Congress for an exciting session exploring the impact of understanding plaque volume and composition for clinical care. Learn about implementing plaque analysis in practice, and the importance of LRNC (lipod rich necrotic core). Hear how Elucid’s software can make a difference. 🎤 Featuring speakers Dr Mark Rabbat MD,FSCCT,FACC,FAHA from Loyola and Dr Matthew Budoff from UCLA. Full breakfast provided! 🍳🥓☕️ Thank you Society of Cardiovascular Computed Tomography ! #SCCT2024 #YesCCT
-